Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1500 participants
OBSERVATIONAL
2009-01-15
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
European Society of Cardiology recommend risk stratification for patients with AHF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Stratification Using MEESSI-AHF Scale in ED and Impact on AHF Outcomes
NCT05919225
Evaluate the Predictive Impact of the EHMRG
NCT05632263
Heart Risk 6 Scale in Emergency Department Acute Heart Failure Patients
NCT06664073
Acute Heart Failure Study in Patients Admitted to Emergency Department for Dyspnea
NCT02835963
Prospective Validation of the Emergency Heart Failure Mortality Risk Grade (EHMRG) Score in Patients With Acute Heart Failure in the Emergency Department
NCT05710302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The MEESSI-AHF risk model includes 13 variables readily available on arrival to Emergency Department. The 40% of patients classified as LOW RISK (30-day mortality: \<2%) should be considered as potential candidates to be early discharged from Emergency Department without admission after adequate response to initial treatment. The 10% of patients classified as VERY HIGH RISK (30-day mortality: \>2%) may clearly benefit from hospital admission.
Objective: To externally validate the MEESSI-AHF score in another country.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MEESSI score
The score aimed to predict the AHF patient's future in the month following management for ED
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient admitted to emergencies with final diagnosis of AHF according to the opinion of two emergency experts after consulting the data from the clinical examination, cardiac echocardiography, and BNP level.
* Subject who accept to participate in the research
Exclusion Criteria
* Patient with coronary syndrome with ST segment elevation
* Other causes of dyspnea
* Impossibility of giving the patient informed information
* Pregnant woman
18 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Monastir
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr. Semir Nouira
Pr.Semir Nouira chef of emergency deparment
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Semir Nouira, Pr
Role: PRINCIPAL_INVESTIGATOR
University of Monastir
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emergency department of University hospital Fattouma Bourguiba
Monastir, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEESSI 2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.